Celgene International Sárl Release: Continuous Treatment with REVLIMID(R) for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant Evaluated by Intergroupe Francophone du Myelome (IFM) of Phase III Study (IFM 2005 02)

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) today announced that updated data from an Intergroupe Francophone du Myelome clinical study under the sponsorship of the University Hospital of Toulouse were presented at the 52nd Annual Meeting of the American Society of Hematology.